Amedeo Smart

Free Medical Literature Service


 

Amedeo

Gynecology

  Free Subscription

Articles published in
Cancer
    December 2026
  1. PHILLIPS SA, Bandi P, Star J, Temkin SM, et al
    Cervical cancer risk reduction in the era of human papillomavirus vaccination.
    Cancer. 2026;132:e70679.
    >> Share

    November 2026
  2. QIU C, Hogdall C, Yang H, Yang WL, et al
    Biologic and immunologic characteristics of ovarian cancers that are associated with p53 autoantibodies.
    Cancer. 2026;132:e70672.
    >> Share

    October 2026
  3. BREEN KE, Vashisth S, Liu YL
    Cancer risks associated with BRCA1 and BRCA2: Overview and management.
    Cancer. 2026;132:e70635.
    >> Share

  4. NIXON AB, Enserro DM, Bender DP, Liu Y, et al
    Blood-based biomarkers in patients with recurrent, persistent, or metastatic endometrial cancer treated with olaparib and cediranib: Results from NRG-GY012.
    Cancer. 2026;132:e70649.
    >> Share

  5. SU L, Burcu M, Ports K, Gradinariu V, et al
    Progression-free survival and overall survival in the first-line treatment of BRCA wild-type advanced epithelial ovarian cancer: An analysis of patient-level data pooled from historical clinical trials.
    Cancer. 2026;132:e70630.
    >> Share

    September 2026
  6. VENEZIANI AC, Venegas L, Oza AM
    The evolving role of immunotherapy in ovarian cancer.
    Cancer. 2026;132:e70581.
    >> Share

  7. MAZZITELLI N, Star J, Meggett K, Han X, et al
    Prevalence of breast, cervical, and colorectal cancer screening among adults according to disability type and difficulty level, United States, 2021 and 2023.
    Cancer. 2026;132:e70557.
    >> Share

  8. MANNING WB, Youssef AM, Yeku OO
    IMMU-NO versus yes: Applicability of immune checkpoint inhibitors in gynecologic cancers.
    Cancer. 2026;132:e70611.
    >> Share

  9. SETIAWATI D, Muchsin W, Sophan A
    Gynecologic cancers in low- and middle-income countries: Bridging the survival gap.
    Cancer. 2026;132:e70518.
    >> Share

    August 2026
  10. DE BEIJER IAE, van den Oever SR, Lawal OA, Button A, et al
    Sexual health behaviors and contraceptive practices among Canadian childhood, adolescent, and young adult cancer survivors and controls.
    Cancer. 2026;132:e70560.
    >> Share

    July 2026
  11. WIDICK PC, Wright AA, Liu JF
    Maintenance therapy in gynecologic malignancies: Current and future state.
    Cancer. 2026;132:e70517.
    >> Share

  12. ARENA L, Alizai Q, Elemosho A, Chatzipanagiotou OP, et al
    Sexual orientation and gender identity based disparities in colorectal, cervical, and breast cancer screening in the United States.
    Cancer. 2026;132:e70462.
    >> Share

    June 2026
  13. BARQUIN A, Kasherman L, Lheureux S, Madariaga A, et al
    Antibody-drug conjugates in gynecologic cancers.
    Cancer. 2026;132 Suppl 1:e70417.
    >> Share

    May 2026
  14. TELLES R, Thaker PH, Goodheart MJ, Penedo FJ, et al
    Rethinking depression diagnosis in ovarian cancer: The role of somatic symptoms.
    Cancer. 2026;132:e70344.
    >> Share

  15. LI L, Song N, Zhang D, Li Y, et al
    Multigene germline testing for epithelial ovarian cancer in China.
    Cancer. 2026;132:e70395.
    >> Share

  16. LAWRENCE L
    HRSA recommends offering self-collection for cervical cancer screening.
    Cancer. 2026;132:e70369.
    >> Share

    March 2026
  17. WERNER HMJ, van Dijk FAH, Vrede SW, van den Bosch AAS, et al
    The impact of the patient macroenvironment on molecular subgroups in endometrial cancer.
    Cancer. 2026;132:e70333.
    >> Share

  18. HAN K
    Advancing molecular residual disease detection in cervical cancer through next-generation sequencing of circulating human papillomavirus DNA.
    Cancer. 2026;132:e70352.
    >> Share

    February 2026
  19. TAMRAKAR VK, Sharma K, Singh P, Bhargava A, et al
    Cervical cancer elimination in India: Repurposing diagnostics, vaccination, and accelerating policy for the 2030 target.
    Cancer. 2026;132:e70292.
    >> Share

  20. BONLOKKE S, Stougaard M, Sorensen BS, Parner E, et al
    Ultrasensitive next-generation sequencing-based detection of circulating human papillomavirus DNA for cervical cancer recurrence monitoring.
    Cancer. 2026;132:e70282.
    >> Share

  21. LAWRENCE L
    Immunochemotherapy regimen demonstrates survival benefits for patients with platinum-resistant ovarian cancer.
    Cancer. 2026;132:e70251.
    >> Share


  22. Correction to "Association of alcohol intake over the lifetime with colorectal adenoma and colorectal cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial".
    Cancer. 2026;132:e70324.
    >> Share

  23. SHAN Y, Ding B, Ji F, Lin H, et al
    T-cell receptor-like chimeric antigen receptor T cells targeting mesothelin: A first-in-human dose-escalation trial for platinum-resistant advanced ovarian cancer.
    Cancer. 2026;132:e70279.
    >> Share

  24. O'CONNELL CP, Berndt SI, Chudy-Onwugaje K, Kunzmann A, et al
    Association of alcohol intake over the lifetime with colorectal adenoma and colorectal cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Cancer. 2026;132:e70201.
    >> Share

    January 2026
  25. LAWRENCE L
    Adjuvant chemoradiation offers minimal survival improvements over radiation alone in intermediate-risk, early cervical cancer: Chemoradiation has become the standard of care for patients with locally advanced cervical cancer as well as high-risk featu
    Cancer. 2026;132:e70207.
    >> Share

  26. CHOI HL, Kim B, Mark Park YM, Yoo JE, et al
    Metabolic obesity phenotypes and breast cancer risk before and after menopause: A nationwide cohort study in South Korea.
    Cancer. 2026;132:e70244.
    >> Share

    November 2025
  27. YE Z, Zhao Y, Wang J, Wang Q, et al
    Pooled performance of urinary human papillomavirus (HPV) testing for the presence of cervical HPV.
    Cancer. 2025;131:e70175.
    >> Share

  28. FITCH KC, Yang JC, Ryan ES, Monuszko KA, et al
    Preferences of BRCA mutation carriers for attributes of risk-reducing surgical options for breast and ovarian cancer.
    Cancer. 2025;131:e70148.
    >> Share

    October 2025
  29. LIN KY, Farley JH
    Putting a spotlight on current chemotherapeutic options for recurrent ovarian clear cell carcinoma.
    Cancer. 2025;131:e70112.
    >> Share

    September 2025
  30. YOSHINO Y, Furusawa A, Nara K, Taguchi A, et al
    Optimizing treatment for platinum-resistant ovarian clear cell carcinoma: Efficacy of gemcitabine and combination therapy with bevacizumab.
    Cancer. 2025;131:e70071.
    >> Share

    August 2025
  31. VISTAD I, Skorstad M, Berntsen S, Demmelmaier I, et al
    Empowerment and quality of life in gynecological cancer survivors: Outcomes from a multicenter quasi-experimental cohort study from Norway (the LETSGO trial).
    Cancer. 2025;131:e70040.
    >> Share

  32. MACDUFFIE E, McCallister C, George J, Monare B, et al
    Assessing the impact of multidisciplinary team gynecological oncology care in Botswana: A potential model for low- and middle-income countries.
    Cancer. 2025;131:e70006.
    >> Share

    July 2025
  33. FONTVIEILLE E, Jansana A, Peruchet-Noray L, Cordova R, et al
    Body mass index and breast cancer risk among postmenopausal women with and without cardiometabolic diseases: Findings from two prospective cohort studies in Europe.
    Cancer. 2025;131:e35911.
    >> Share

    May 2025
  34. DUSKA LR, Lim J, Calderon Boyle TA, Guinter M, et al
    The BEV1L study: Do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?
    Cancer. 2025;131:e35821.
    >> Share

  35. SCHNEIDER DT, Witowski A, Abele M, Benesch M, et al
    Testicular and ovarian Juvenile granulosa cell tumors in children and adolescents: Analysis of 113 patients registered to the German Registry for Rare Pediatric Tumors (STEP).
    Cancer. 2025;131:e35861.
    >> Share

  36. HARRIS AK, Nelson AT, Watson D, Mallinger PHR, et al
    Ovarian juvenile granulosa cell tumor: A report from the International Ovarian and Testicular Stromal Tumor and International Pleuropulmonary Blastoma/DICER1 Registries.
    Cancer. 2025;131:e35862.
    >> Share

  37. EBOTT J, Grant KR, Farley J, Stasenko M, et al
    Gender equity gap persists, addressing the root cause through the lens of gynecologic oncology: An evidenced-based review.
    Cancer. 2025;131:e35843.
    >> Share

  38. HUANG CC, Ayala-Peacock DN, Stephens SJ, Chino JP, et al
    Recent advances in gynecologic radiation oncology.
    Cancer. 2025;131:e35888.
    >> Share

    April 2025
  39. KUNOS CA, Chauhan A
    Prospects for radioimmunotherapy panaceas in gynecologic oncology.
    Cancer. 2025;131:e35841.
    >> Share

  40. FREY MK, Liu JF
    Shedding LIGHT on the changing landscape of poly-ADP ribose polymerase inhibitors in ovarian cancer.
    Cancer. 2025;131:e35800.
    >> Share

  41. APPLEBAUM JC, Ginsburg ES
    Parenthood after cancer: The critical, yet complex, contribution of gestational carriers.
    Cancer. 2025;131:e35853.
    >> Share

  42. ELLINGTON TD, Wardell AC, Deal AM, Mersereau J, et al
    In vitro fertilization with cryopreserved oocytes or embryos after cancer: The role of gestational carriers.
    Cancer. 2025;131:e35844.
    >> Share

    March 2025
  43. RAYCHAUDHURI S, McLaughlin E, Pennell ML, Stefanick M, et al
    The relationship between cardiometabolic abnormalities and mortality in the Women's Health Initiative: A comparison of associations among women with cancer to women without cancer.
    Cancer. 2025;131:e35804.
    >> Share

  44. KARPEL HC, Zambrano Guevara LM, Rimel BJ, Hacker KE, et al
    The missing data: A review of gender and sex disparities in research.
    Cancer. 2025;131:e35769.
    >> Share

  45. SOROURI K, Glass K, Ruddy KJ, Warner E, et al
    Anti-Mullerian hormone for assessing ovarian toxicity of cancer treatment in young women: It's complicated.
    Cancer. 2025;131:e35774.
    >> Share

  46. BAE HS, Temkin SM
    Cervical cancer stigma - A silent barrier to the elimination of cervical cancer.
    Cancer. 2025;131:e35776.
    >> Share

  47. NIERENGARTEN MB
    More evidence on benefits of HIPEC for recurrent ovarian cancer.
    Cancer. 2025;131:e35754.
    >> Share

    February 2025
  48. PENNINX BMF, Samson MJ, Schnog JB
    Pembrolizumab with chemoradiotherapy followed by pembrolizumab for stage III-IVa cervical cancer: is the ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial practice changing?
    Cancer. 2025;131:e35749.
    >> Share

  49. DUSKA LR, Petroni GR, Thaker PH, Crane EK, et al
    Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer.
    Cancer. 2025;131:e35757.
    >> Share

  50. NIERENGARTEN MB
    New standard of care for patients with locally advanced cervical cancer.
    Cancer. 2025;131:e35739.
    >> Share

  51. BAEKER BISPO J, Jemal A, Islami F
    Association of mental health treatment receipt with cancer screening among US adults with a history of anxiety or depression.
    Cancer. 2025;131:e35724.
    >> Share

  52. HIPPALGAONKAR N, Huo D, Hoskins KF
    The long road to unbiased estimates of pancreatic cancer incidence in the hereditary breast and ovarian cancer syndrome.
    Cancer. 2025;131:e35722.
    >> Share

  53. NERO C, Trozzi R, Persiani F, Rossi S, et al
    POLE mutations in endometrial carcinoma: Clinical and genomic landscape from a large prospective single-center cohort.
    Cancer. 2025;131:e35731.
    >> Share

  54. TEMKIN SM
    Chronic conditions, cancer disparities, and the unique needs of Black women with ovarian cancer.
    Cancer. 2025;131:e35735.
    >> Share

    January 2025
  55. REN W, Guo X, Liu Z, Wu Y, et al
    Burden of female-specific cancers in China from 1990 to 2021: A systematic analysis for the Global Burden of Disease Study 2021.
    Cancer. 2025;131:e35712.
    >> Share

  56. LIU YL, Mathews CA, Simpkins F, Cadoo KA, et al
    Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis.
    Cancer. 2025;131:e35707.
    >> Share

  57. NIERENGARTEN MB
    Overall survival benefit of pembrolizumab plus chemoradiotherapy for patients with high-risk locally advanced cervical cancer.
    Cancer. 2025;131:e35688.
    >> Share

  58. MAHALINGAM D, Owonikoko TK, Delpassand E, Mulcahy MF, et al
    A trial of radiolabeled antibody yttrium-90-FF-21101 for the treatment of advanced ovarian and other cancers.
    Cancer. 2025;131:e35680.
    >> Share

  59. RICHARDS AR, Johnson CE, Montalvo NR, Alberg AJ, et al
    Comorbid conditions and survival among Black women with ovarian cancer.
    Cancer. 2025;131:e35694.
    >> Share

  60. PANDEY AS, Drogan C, Huo D, Postula K, et al
    Anticipation in families with MLH1-associated Lynch syndrome.
    Cancer. 2025;131:e35589.
    >> Share

    December 2024
  61. HENDRIX EL, Chollette VY, Wentzensen N, Loukissas JK, et al
    Federal Cervical Cancer Collaborative: Improving cervical cancer prevention through vaccination, screening, and management in safety-net settings of care.
    Cancer. 2024 Dec 11. doi: 10.1002/cncr.35655.
    >> Share

    November 2024
  62. NIERENGARTEN MB
    Common strategy to diagnose endometrial cancer may not be reliable for Black women.
    Cancer. 2024;130:3783.
    >> Share

  63. NIERENGARTEN MB
    Women with more severe forms of endometriosis have a nearly 10-fold higher risk of ovarian cancer.
    Cancer. 2024;130:3784.
    >> Share

    October 2024
  64. KONDO T, Matsuki E, Takaku T, Watanabe N, et al
    Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
    Cancer. 2024 Oct 30. doi: 10.1002/cncr.35611.
    >> Share

  65. JOHNSON HM, Song J, Warneke CL, Martinez AL, et al
    Outcomes of patients treated with chemotherapy for breast cancer during pregnancy compared with nonpregnant breast cancer patients treated with systemic therapy.
    Cancer. 2024 Oct 29. doi: 10.1002/cncr.35619.
    >> Share

  66. WILSON EM, Huang R, Jones KD, Hagemann IS, et al
    Challenges in implementation of molecular classification in early stage endometrial cancer-An NRG Oncology cooperative group mixed-methods study.
    Cancer. 2024 Oct 17. doi: 10.1002/cncr.35596.
    >> Share

  67. NIERENGARTEN MB
    Excellent outcomes with radiation alone for localized recurrences of endometrial cancer.
    Cancer. 2024;130:3400.
    >> Share

    September 2024
  68. MEGHANI K, Grover S
    Reply to "Assessing the impact of HIV status on cervical cancer treatment outcomes in Botswana: A commentary".
    Cancer. 2024 Sep 10. doi: 10.1002/cncr.35553.
    >> Share

  69. JEYARAJ G
    Assessing the impact of HIV status on cervical cancer treatment outcomes in Botswana: A commentary.
    Cancer. 2024 Sep 10. doi: 10.1002/cncr.35545.
    >> Share

    August 2024
  70. SULLIVAN MW, Graves S, Adkoli A, Zhou Q, et al
    Factors associated with an inconclusive result from commercial homologous recombination deficiency testing in ovarian cancer.
    Cancer. 2024 Aug 16. doi: 10.1002/cncr.35523.
    >> Share

  71. ISSAKA RB, Ibekwe LN, Todd KW, Burnett-Hartman AN, et al
    Association between racial residential segregation and screening uptake for colorectal and cervical cancer among Black and White patients in five US health care systems.
    Cancer. 2024 Aug 9. doi: 10.1002/cncr.35514.
    >> Share

    July 2024
  72. PEREZ L, Dioun S, Primiano M, Blank SV, et al
    Considering screening for hereditary cancer syndromes at the time of obstetrical prenatal carrier screening.
    Cancer. 2024 Jul 22. doi: 10.1002/cncr.35480.
    >> Share

  73. MACKAY H, Fernandes I
    Cell-free DNA in recurrent and metastatic endometrial cancer: The future is now? Promises and potential pitfalls.
    Cancer. 2024 Jul 10. doi: 10.1002/cncr.35448.
    >> Share

  74. ELGHAZALY H, Azim HA, Rugo HS, Cameron D, et al
    Tailoring neo/adjuvant systemic therapy in breast cancer: "The advent of a personalized approach"-The Breast-Gynecological and Immuno-Oncology International Cancer Conference (BGICC) consensus and recommendations.
    Cancer. 2024 Jul 10. doi: 10.1002/cncr.35389.
    >> Share

  75. BANERJEE S, Hasson SP
    Top advances of the year: Immunotherapy in endometrial cancer.
    Cancer. 2024 Jul 4. doi: 10.1002/cncr.35417.
    >> Share

  76. NIERENGARTEN MB
    Significant overall survival benefit with dostarlimab plus chemotherapy in advanced endometrial cancer.
    Cancer. 2024;130:2245.
    >> Share

  77. NIERENGARTEN MB
    Favorable overall survival trend with pembrolizumab plus chemotherapy for endometrial cancer.
    Cancer. 2024;130:2246.
    >> Share

    June 2024
  78. BEAVIS AL, Wethington SL, Yu R, Topel KM, et al
    Differential utilization of the online patient portal for completion of health-related social needs screening during routine gynecologic cancer care.
    Cancer. 2024 Jun 29. doi: 10.1002/cncr.35376.
    >> Share


  79. Erratum to "Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials".
    Cancer. 2024 Jun 7. doi: 10.1002/cncr.35344.
    >> Share

  80. BLANC-DURAND F, Camilleri GM, Bayle A, Aldea M, et al
    Clinical utility of comprehensive liquid molecular profiling in patients with advanced endometrial cancer.
    Cancer. 2024 Jun 2. doi: 10.1002/cncr.35381.
    >> Share

    May 2024
  81. LOGGERS ET, Chugh R, Federman N, Hartner L, et al
    Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study.
    Cancer. 2024 May 4. doi: 10.1002/cncr.35324.
    >> Share

    April 2024
  82. DUSKA LR, Podwika SE, Randall LM
    Top advances of the year: Cervical cancer.
    Cancer. 2024 Apr 23. doi: 10.1002/cncr.35334.
    >> Share

  83. STERPETTI AV, Gabriele R, Iannone I, Dimarzo L, et al
    National organized screening programs for breast, colorectal, and cervical cancer reduce socioeconomic disparities, but it is not enough.
    Cancer. 2024 Apr 20. doi: 10.1002/cncr.35335.
    >> Share

  84. RUAN Y, Heer E, Brenner DR
    Reply to "National organized screening programs for breast, colorectal, and cervical cancer reduce socioeconomic disparities, but it is not enough".
    Cancer. 2024 Apr 20. doi: 10.1002/cncr.35339.
    >> Share

  85. NIERENGARTEN MB
    Promising new treatment approaches for locally advanced cervical cancer.
    Cancer. 2024;130:1192.
    >> Share

  86. ERICKSON BK, Slomovitz B, Powell M, Eskander RN, et al
    Top advances of the year: Uterine cancer.
    Cancer. 2024 Apr 15. doi: 10.1002/cncr.35321.
    >> Share

    March 2024
  87. MEGHANI K, Puri P, Bazzett-Matabele L, Vuylsteke P, et al
    Significance of HIV status in cervical cancer patients receiving curative chemoradiation therapy, definitive radiation alone, or palliative radiation in Botswana.
    Cancer. 2024 Mar 26. doi: 10.1002/cncr.35289.
    >> Share

  88. LEE H, Baeker Bispo J, Pal Choudhury P, Wiese D, et al
    Factors contributing to differences in cervical cancer screening in rural and urban community health centers.
    Cancer. 2024 Mar 25. doi: 10.1002/cncr.35265.
    >> Share

  89. MICHEL AD, Fontenot HB, Fuzzell L, Brownstein NC, et al
    Attitudes toward the American Cancer Society's 2020 cervical cancer screening guidelines: A qualitative study of a national sample of US clinicians.
    Cancer. 2024 Mar 4. doi: 10.1002/cncr.35269.
    >> Share

    February 2024
  90. LIU YL, Weigelt B
    A tale of two pathways: Review of immune checkpoint inhibitors in DNA mismatch repair-deficient and microsatellite instability-high endometrial cancers.
    Cancer. 2024 Feb 29. doi: 10.1002/cncr.35267.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016